MXC.AX Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (2 bal. 2024 @ 08:10):

MGC Pharmaceuticals Limited, a bio-pharma company, develops and supplies phytomedicines in worldwide. The company produces and supplies medicinal cannabis products; and non-cannabis phytomedicines...

Stats
Dzisiejszy wolumen	47 232.00
Średni wolumen	23 177.00
Kapitalizacja rynkowa	18.42M
EPS	$0 ( 2024-02-25 )
Następna data zysków	( $0 ) 2024-07-26
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.130
ATR14	$0.0240 (5.78%)

Wolumen Korelacja

Długi: -0.04 (neutral)

Krótki: 0.36 (neutral)

Signal:(47.63) Neutral

MGC Pharmaceuticals Ltd Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

MGC Pharmaceuticals Ltd Korelacja - Waluta/Towar

0.30
( neutral )

-0.03
( neutral )

0.00
( neutral )

0.57
( weak )

-0.49
( neutral )

-0.66
( moderate negative )

MGC Pharmaceuticals Ltd Finanse

Annual	2023
Przychody:	$3.39M
Zysk brutto:	$698 740 (20.63 %)
EPS:	$-7.07

FY	2023
Przychody:	$3.39M
Zysk brutto:	$698 740 (20.63 %)
EPS:	$-7.07

FY	2022
Przychody:	$4.73M
Zysk brutto:	$1.56M (33.01 %)
EPS:	$-7.93

FY	2021
Przychody:	$2.96M
Zysk brutto:	$1.31M (44.23 %)
EPS:	$-0.0115

Financial Reports:

No articles found.

MGC Pharmaceuticals Ltd

MGC Pharmaceuticals Limited, a bio-pharma company, develops and supplies phytomedicines in worldwide. The company produces and supplies medicinal cannabis products; and non-cannabis phytomedicines. Its principal product candidates include CimetrA, which is in phase III clinical trial for the symptomatic treatment of early COVID-19; CannEpil, a phase IIb cannabis-based therapy for drug-resistant Epilepsy; and CogniCann that is in phase II clinical trial for the symptomatic relief of Dementia. The company also provides ArtemiC range of products and cannabinoid products, as well as non-pharma products. In addition, it offers consulting services, including clinical research services. The company was formerly known as Erin Resources Limited and changed its name to MGC Pharmaceuticals Limited in December 2015. MGC Pharmaceuticals Limited was founded in 2014 and is based in West Perth, Australia.